CAMBRIDGE, Mass., March 17, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be reporting on the chemistry leading to the discovery of its novel Hedgehog signaling pathway inhibitor, IPI-926, during the 237th American Chemical Society (ACS) National Meeting & Exposition, being held in Salt Lake City, Utah from March 22 through March 26, 2009.
The schedule of presentations is as follows:
Wednesday, Mar. 25, 2009: 9:00 a.m. - 12:35 p.m. MDT Oral Session Title: Discovery of IPI-926, a Semisynthetic Clinical Candidate that Targets the Hedgehog Pathway Presenter: Martin Tremblay, Associate Director, Chemistry Location: Ballrooms H&J Sunday, Mar. 22, 2009: 7:00 - 9:00 p.m. MDT Poster Session Title: Synthesis and Structure Activity Relationship of D-Homo Cyclopamine Analogs: 3-Substituted Analogs Presenter: Martin Tremblay, Associate Director, Chemistry Location: Poster Hall 5 Sunday, Mar. 22, 2009: 7:00 - 9:00 p.m. MDT Poster Session Title: Synthesis and Structure Activity Relationship of D-Homo Hedgehog Antagonists: 7-Membered A-Ring Lactam Analogs Presenter: Andre Lescarbeau, Senior Scientist, Chemistry Location: Poster Hall 5 Sunday, Mar. 22, 2009: 7:00 - 9:00 p.m. MDT Poster Session Title: Synthesis and Structure Activity Relationship of D-Homo Cyclopamine Analogs: A-Ring Fused Heterocyclic Analogs Presenter: Michael Grogan, Lead Senior Scientist, Chemistry Location: Poster Hall 5
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity's two most advanced programs in Hsp90 inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.